Abstract
Background: The combinations of PARP inhibitor (PARPi) and platinum-based drugs are gaining more interest as first line therapy for early-stage breast cancer. The I-SPY2 trial (NCT01042379) qualified different DNA-Damage-Repair (DDR) deficiency biomarkers that predict response to DNA damage agents. Here we aimed to translate the I-SPY2 research findings to a robust clinical grade platform signature to predict sensitivity to PARPi and platinum-based chemotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
